HC Wainwright Has Bearish Forecast for RIGL FY2026 Earnings

Key Points

• HC Wainwright cut its FY2026 EPS forecast for Rigel Pharmaceuticals to $2.84 from $3.26, below the $2.98 consensus estimate, while maintaining a Buy rating and an $85 price target.
• Rigel reported quarterly EPS of $0.65, missing the $0.92 analyst consensus, though revenue of $80.89 million slightly exceeded estimates of $80 million.
• Analyst views are mixed: the stock has a consensus Hold rating and $66.75 price target, despite Buy ratings and higher targets from HC Wainwright and Citigroup.

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL - Free Report) - Investment analysts at HC Wainwright reduced their FY2026 earnings per share estimates for shares of Rigel Pharmaceuticals in a research note issued on Friday, November 6th. HC Wainwright analyst J. Pantginis now anticipates that the biotechnology company will post earnings per share of $2.84 for the year, down from their previous estimate of $3.26. HC Wainwright has a "Buy" rating and a $85.00 price objective on the stock. The consensus estimate for Rigel Pharmaceuticals' current full-year earnings is $2.98 per share. HC Wainwright also issued estimates for Rigel Pharmaceuticals' FY2028 earnings at $5.21 EPS, FY2029 earnings at $5.96 EPS and FY2030 earnings at $7.03 EPS.

Rigel Pharmaceuticals (NASDAQ:RIGL - Get Free Report) last issued its quarterly earnings data on Thursday, November 5th. The biotechnology company reported $0.65 earnings per share for the quarter, missing analysts' consensus estimates of $0.92 by ($0.27). Rigel Pharmaceuticals had a return on equity of 22.95% and a net margin of 116.30%. The business had revenue of $80.89 million during the quarter, compared to the consensus estimate of $80.00 million.

Several other analysts have also recently weighed in on the stock. Zacks Research cut shares of Rigel Pharmaceuticals from a "hold" rating to a "strong sell" rating in a report on Wednesday, October 14th. Piper Sandler reissued a "neutral" rating and set a $49.00 price objective (up from $40.00) on shares of Rigel Pharmaceuticals in a research report on Monday, August 17th. Weiss Ratings upgraded shares of Rigel Pharmaceuticals from a "buy (b-)" rating to a "buy (b)" rating in a report on Thursday, October 8th. Citigroup raised their target price on shares of Rigel Pharmaceuticals from $83.00 to $86.00 and gave the stock a "buy" rating in a research report on Monday. Finally, Cantor Fitzgerald lifted their target price on shares of Rigel Pharmaceuticals from $43.00 to $47.00 and gave the company a "neutral" rating in a research note on Friday. Three analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of "Hold" and a consensus price target of $66.75.

Rigel Pharmaceuticals Stock Up 6.1%

Shares of Rigel Pharmaceuticals stock opened at $42.05 on Tuesday. The company has a market cap of $777.92 million, a PE ratio of 2.71 and a beta of 1.28. The business has a 50 day moving average of $47.70 and a 200 day moving average of $37.50. Rigel Pharmaceuticals has a 52 week low of $24.95 and a 52 week high of $52.60.

Institutional Trading of Rigel Pharmaceuticals

Hedge funds and other institutional investors have recently modified their holdings of the business. BlackRock Inc. purchased a new position in shares of Rigel Pharmaceuticals during the second quarter valued at approximately $75,886,000. Assenagon Asset Management S.A. purchased a new stake in shares of Rigel Pharmaceuticals in the 3rd quarter worth approximately $25,793,000. Dimensional Fund Advisors LP grew its stake in shares of Rigel Pharmaceuticals by 37.1% in the 1st quarter. Dimensional Fund Advisors LP now owns 379,541 shares of the biotechnology company's stock worth $10,259,000 after buying an additional 102,729 shares during the last quarter. Ritholtz Wealth Management grew its stake in shares of Rigel Pharmaceuticals by 13.9% in the 3rd quarter. Ritholtz Wealth Management now owns 107,590 shares of the biotechnology company's stock worth $5,180,000 after buying an additional 13,140 shares during the last quarter. Finally, Bank of America Corp DE bought a new position in Rigel Pharmaceuticals during the 2nd quarter valued at approximately $4,832,000. 66.23% of the stock is owned by hedge funds and other institutional investors.

Trending Headlines about Rigel Pharmaceuticals

Here are the key news stories impacting Rigel Pharmaceuticals this week:

• Positive Sentiment: Citigroup raised its price target to $86 from $83 and maintained a Buy rating, signaling substantial upside in the analyst’s view. Citigroup recommendations
• Positive Sentiment: HC Wainwright also reiterated Buy with an $85 target. The favorable rating and target may support sentiment despite the firm’s lower forecasts.
• Negative Sentiment: HC Wainwright cut its EPS estimates for fiscal 2026, 2028, 2029 and 2030 to $2.84, $5.21, $5.96 and $7.03, respectively. The revisions reduce expectations for future earnings growth and may temper the benefit of the bullish price targets.
• Positive Sentiment: A separate analyst report raised Rigel’s price target to $47, another upward revision, although that target is below the $85–$86 objectives cited by other firms. Rigel Pharmaceuticals price target raised to $47

Rigel Pharmaceuticals Company Profile

Rigel Pharmaceuticals, Inc NASDAQ: RIGL is a biotechnology company focused on developing and commercializing therapies for hematologic diseases, cancer and immune-related disorders. Founded in 1996 and headquartered in South San Francisco, California, the company uses small-molecule drug discovery and kinase biology to develop medicines that address unmet medical needs.

Rigel's primary commercial product is Tavalisse (fostamatinib disodium), an oral spleen tyrosine kinase inhibitor approved in the United States for treating thrombocytopenia in adults with chronic immune thrombocytopenia who have had an insufficient response to previous treatment.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.